[Problems in the management of HIV infection in clinical practice. Patients still on dual therapy 8 years after the introduction of HAART].
Eight years after the introduction of HAART as the standard therapy of HIV disease, around one fifth of treated patients of our cohort still rely on isolated dual nucleoside analogue administration, mostly due to an apparently effective treatment initiated with these last drugs before the HAART era, or severe intolerance to triple regimens based on protease inhibitors or non-nucleoside reverse transcriptase inhibitors, or patient's refusal of HAART. Three representative case reports are described, and their implications discussed on the ground of current guidelines of antiretroviral therapy and common clinical practice.
Manfredi
Roberto
R
Sezione di Malattie Infettive, Dipartimento di Medicina Clinica Specialistica e Sperimentale, Università degli Studi di Bologna.
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D019090:Case Management; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016312:Treatment Refusal; D014766:Viremia / Q000188:drug therapy
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors